Abstract
Collagenase clostridium histolyticum (CCH) was approved for the treatment of Peyronie’s disease (PD) in December of 2013. Recently, further research has supported its use. The aim of this study was to objectively evaluate the effects of CCH on penile curvature associated with Peyronie’s disease at our high volume institution. Since the approval of CCH for PD, 45 men have undergone between 1 and 4 treatment cycles (mean 3.13, standard deviation (SD) = 0.87) at our institution. Primary as well as secondary curvature, if any, was measured before beginning therapy and after each cycle of therapy. The degree of curvature was compared. We also questioned these men about their subjective experience with CCH. The mean age of this cohort was 55.7 years (range 35–70). The mean primary curvature was 53.6° (SD = 16.5). Post-treatment mean primary curvature was 48.2° (SD = 19.5), p = 0.10. Secondary curvature was reduced from 24.1° (SD = 11.3) to 20.4° (SD = 11.5) before and after treatment with CCH, respectively, p = 0.27. There were two tunical ruptures in this series after which both ceased therapy with CCH. Additionally, 37/45 patients in this series expressed some degree of dissatisfaction in their post-therapy visits with most of these men stating that they did not notice a change in their curvature. CCH remains an option for the treatment of PD. Predictors of success, however, are lacking. Our experience showed a less-robust response to CCH than previous studies and underscores the need for effective and clear patient counseling prior to the initiation of therapy with CCH for PD in the post-FDA-approval setting.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie’s disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.
Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187:2268–74.
Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol. 1993;149:56–8.
Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med. 2015;12:248–58.
Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116:650–6.
Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for Peyronie’s disease. J Urol. 2016;195:1051–6.
Terlecki RP, Rasper AM. Data vs dogma in Peyronie’s disease. Int Braz J Urol. 2016;42:1058–61.
Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176:394–8.
Abdel Raheem A, Capece M, Kalejaiye O, et al. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int. 2017;120:717–23.
Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie’s disease. J Sex Med. 2016;13:684–9.
Coyne KS, Currie BM, Thompson CL, Smith TM. Responsiveness of the Peyronie’s disease questionnaire (PDQ). J Sex Med. 2015;12:1072–9.
Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359–74.
Levine LA, Lenting EL. A surgical algorithm for the treatment of Peyronie’s disease. J Urol. 1997;158:2149–52.
Papagiannopoulos D, Yura E, Levine L. Examining postoperative outcomes after employing a surgical algorithm for management of Peyronie’s disease: a single-institution retrospective review. J Sex Med. 2015;12:1474–80.
Chen JY, Hockenberry MS, Lipshultz LI. Objective assessments of Peyronie's disease. Sex Med Rev. 2018;6:438–45.
Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190:627–34.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
LL is a consultant for Boston Scientific, Coloplast Corporation, and Endo Pharmaceuticals. He is a lecturer for Boston Scientific, Coloplast Corporation, and Abbvie Pharmaceuticals. The remaining authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Tsambarlis, P.N., Yong, R. & Levine, L.A. Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease. Int J Impot Res 31, 15–19 (2019). https://doi.org/10.1038/s41443-018-0063-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-018-0063-1
This article is cited by
-
Re: Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease
International Journal of Impotence Research (2020)
-
Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease
International Journal of Impotence Research (2020)
-
Engineering of erectile tissue: the state and future of corporal restoration
World Journal of Urology (2020)
-
Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond
World Journal of Urology (2020)
-
Collagenase Clostridium Histolyticum: A Review in Peyronie’s Disease
Clinical Drug Investigation (2020)